IVECO GROUP NV (IVG.MI) Stock Fundamental Analysis
BIT:IVG - Euronext Milan - NL0015000LU4 - Common Stock - Currency: EUR
Overall IVG gets a fundamental rating of 5 out of 10. We evaluated IVG against 105 industry peers in the Machinery industry. IVG has an average financial health and profitability rating. IVG scores decently on growth, while it is valued quite cheap. This could make an interesting combination.
1. Profitability
1.1 Basic Checks
IVG had positive earnings in the past year.
IVG had a positive operating cash flow in the past year.
Of the past 5 years IVG 4 years were profitable.
IVG had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
IVG's Return On Assets of 1.30% is on the low side compared to the rest of the industry. IVG is outperformed by 60.58% of its industry peers.
IVG has a Return On Equity of 9.60%. This is in the better half of the industry: IVG outperforms 66.35% of its industry peers.
The Return On Invested Capital of IVG (5.45%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.3% | ||
| ROE | 9.6% | ||
| ROIC | 5.45% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IVG's Profit Margin of 1.50% is in line compared to the rest of the industry. IVG outperforms 40.38% of its industry peers.
In the last couple of years the Profit Margin of IVG has grown nicely.
IVG has a Operating Margin (6.00%) which is comparable to the rest of the industry.
IVG's Operating Margin has been stable in the last couple of years.
With a Gross Margin value of 17.35%, IVG is not doing good in the industry: 83.65% of the companies in the same industry are doing better.
IVG's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6% | ||
| PM (TTM) | 1.5% | ||
| GM | 17.35% |
OM growth 3Y12.3%
OM growth 5Y0.85%
PM growth 3Y77.09%
PM growth 5Y26.56%
GM growth 3Y7.43%
GM growth 5Y4.66%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), IVG is destroying value.
There is no outstanding debt for IVG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
IVG has an Altman-Z score of 1.86. This is not the best score and indicates that IVG is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of IVG (1.86) is comparable to the rest of the industry.
The Debt to FCF ratio of IVG is 18.74, which is on the high side as it means it would take IVG, 18.74 years of fcf income to pay off all of its debts.
IVG has a Debt to FCF ratio of 18.74. This is in the lower half of the industry: IVG underperforms 63.46% of its industry peers.
IVG has a Debt/Equity ratio of 1.52. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.52, IVG is not doing good in the industry: 82.69% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.52 | ||
| Debt/FCF | 18.74 | ||
| Altman-Z | 1.86 |
ROIC/WACC0.95
WACC5.76%
2.3 Liquidity
IVG has a Current Ratio of 2.12. This indicates that IVG is financially healthy and has no problem in meeting its short term obligations.
IVG's Current ratio of 2.12 is fine compared to the rest of the industry. IVG outperforms 77.88% of its industry peers.
A Quick Ratio of 1.47 indicates that IVG should not have too much problems paying its short term obligations.
With an excellent Quick ratio value of 1.47, IVG belongs to the best of the industry, outperforming 81.73% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.12 | ||
| Quick Ratio | 1.47 |
3. Growth
3.1 Past
IVG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.65%, which is quite impressive.
The Earnings Per Share has been growing by 32.82% on average over the past years. This is a very strong growth
The Revenue has decreased by -5.70% in the past year.
The Revenue has been growing slightly by 5.06% on average over the past years.
EPS 1Y (TTM)58.65%
EPS 3Y88.31%
EPS 5Y32.82%
EPS Q2Q%451.06%
Revenue 1Y (TTM)-5.7%
Revenue growth 3Y6.52%
Revenue growth 5Y5.06%
Sales Q2Q%-6.56%
3.2 Future
IVG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.24% yearly.
The Revenue is expected to grow by 6.35% on average over the next years.
EPS Next Y14.4%
EPS Next 2Y16.68%
EPS Next 3Y16.8%
EPS Next 5Y16.24%
Revenue Next Year1.79%
Revenue Next 2Y3.71%
Revenue Next 3Y5.05%
Revenue Next 5Y6.35%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 12.35, IVG is valued correctly.
Compared to the rest of the industry, the Price/Earnings ratio of IVG indicates a somewhat cheap valuation: IVG is cheaper than 75.00% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 29.35. IVG is valued rather cheaply when compared to this.
A Price/Forward Earnings ratio of 7.60 indicates a rather cheap valuation of IVG.
91.35% of the companies in the same industry are more expensive than IVG, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.10, IVG is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.35 | ||
| Fwd PE | 7.6 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IVG indicates a rather cheap valuation: IVG is cheaper than 83.65% of the companies listed in the same industry.
65.38% of the companies in the same industry are more expensive than IVG, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.88 | ||
| EV/EBITDA | 4.75 |
4.3 Compensation for Growth
IVG's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
IVG's earnings are expected to grow with 16.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.86
PEG (5Y)0.38
EPS Next 2Y16.68%
EPS Next 3Y16.8%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 2.04%, IVG has a reasonable but not impressive dividend return.
IVG's Dividend Yield is a higher than the industry average which is at 3.07.
Compared to an average S&P500 Dividend Yield of 2.33, IVG has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.04% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
IVG pays out 38.89% of its income as dividend. This is a sustainable payout ratio.
DP38.89%
EPS Next 2Y16.68%
EPS Next 3Y16.8%
BIT:IVG (3/7/2025, 7:00:00 PM)
15.56
-0.62 (-3.86%)
Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap4.22B
Analysts78.67
Price Target16.73 (7.52%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.04% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP38.89%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.3%
Min EPS beat(2)7.26%
Max EPS beat(2)47.35%
EPS beat(4)3
Avg EPS beat(4)27.55%
Min EPS beat(4)-67.17%
Max EPS beat(4)122.78%
EPS beat(8)5
Avg EPS beat(8)10.19%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.06%
Min Revenue beat(2)0.94%
Max Revenue beat(2)1.19%
Revenue beat(4)3
Avg Revenue beat(4)1.24%
Min Revenue beat(4)-6.08%
Max Revenue beat(4)8.93%
Revenue beat(8)4
Avg Revenue beat(8)1.29%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)25.96%
PT rev (3m)19.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.88%
EPS NY rev (1m)4.81%
EPS NY rev (3m)2.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)8.17%
Revenue NY rev (1m)1.06%
Revenue NY rev (3m)-0.68%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.35 | ||
| Fwd PE | 7.6 | ||
| P/S | 0.27 | ||
| P/FCF | 13.88 | ||
| P/OCF | 3.33 | ||
| P/B | 1.73 | ||
| P/tB | 7.92 | ||
| EV/EBITDA | 4.75 |
EPS(TTM)1.26
EY8.1%
EPS(NY)2.05
Fwd EY13.15%
FCF(TTM)1.12
FCFY7.2%
OCF(TTM)4.67
OCFY30.02%
SpS57.55
BVpS8.99
TBVpS1.97
PEG (NY)0.86
PEG (5Y)0.38
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.3% | ||
| ROE | 9.6% | ||
| ROCE | 7.51% | ||
| ROIC | 5.45% | ||
| ROICexc | 6.71% | ||
| ROICexgc | 8.25% | ||
| OM | 6% | ||
| PM (TTM) | 1.5% | ||
| GM | 17.35% | ||
| FCFM | 1.95% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y12.3%
OM growth 5Y0.85%
PM growth 3Y77.09%
PM growth 5Y26.56%
GM growth 3Y7.43%
GM growth 5Y4.66%
F-Score7
Asset Turnover0.87
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.52 | ||
| Debt/FCF | 18.74 | ||
| Debt/EBITDA | 2.34 | ||
| Cap/Depr | 149.07% | ||
| Cap/Sales | 6.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 80.04% | ||
| Profit Quality | 129.92% | ||
| Current Ratio | 2.12 | ||
| Quick Ratio | 1.47 | ||
| Altman-Z | 1.86 |
F-Score7
WACC5.76%
ROIC/WACC0.95
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)302.83%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.65%
EPS 3Y88.31%
EPS 5Y32.82%
EPS Q2Q%451.06%
EPS Next Y14.4%
EPS Next 2Y16.68%
EPS Next 3Y16.8%
EPS Next 5Y16.24%
Revenue 1Y (TTM)-5.7%
Revenue growth 3Y6.52%
Revenue growth 5Y5.06%
Sales Q2Q%-6.56%
Revenue Next Year1.79%
Revenue Next 2Y3.71%
Revenue Next 3Y5.05%
Revenue Next 5Y6.35%
EBIT growth 1Y6.96%
EBIT growth 3Y19.62%
EBIT growth 5Y5.95%
EBIT Next Year82.65%
EBIT Next 3Y28.16%
EBIT Next 5YN/A
FCF growth 1Y26.14%
FCF growth 3YN/A
FCF growth 5Y38.07%
OCF growth 1Y12.82%
OCF growth 3Y26.42%
OCF growth 5Y8.96%